Obeticholic acid - 98%, high purity , Bile acid receptor FXR agonist, CAS No.459789-99-2, Bile acid receptor FXR agonist

Item Number
I193491
Grouped product items
SKUSizeAvailabilityPrice Qty
I193491-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$24.90
I193491-50mg
50mg
3
$95.90
I193491-250mg
250mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$342.90
I193491-1g
1g
3
$999.90
I193491-5g
5g
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$3,496.90

Potent and selective FXR agonist

Basic Description

Synonyms6-ECDCA | INT-747 | 6-Ethylchenodeoxycholic acid | 6-Ethyl-3α,7α-dihydroxycholan-24-oic Acid | OCA | (3α,5β, 6α,7α)-6-ethyl-3,7-dihydroxy-cholan-24-oic acid | 6a-Ethyl-Chenodeoxycholic Acid
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsPotent and selective FXR agonist (EC 50 = 99 nM). Dual FXR/GP-BAR1 ligand. Induces preadiopocyte differentiation. Induces apoptosis. Shows anticholeretic and anti-inflammatory effects and regulates adipose cell function in vivo. Orally active.Obeticholic
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionBile acid receptor FXR agonist
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

AI Insight

Product Properties

ALogP5.7

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid504758867
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/504758867
IUPAC Name (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
INCHI InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1
InChi Key ZXERDUOLZKYMJM-ZWECCWDJSA-N
Canonical SMILES CCC1C2CC(CCC2(C3CCC4(C(C3C1O)CCC4C(C)CCC(=O)O)C)C)O
Isomeric SMILES CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O
PubChem CID 447715
Molecular Weight 420.63

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

16 results found

Lot NumberCertificate TypeDateItem
J2408463Certificate of AnalysisAug 01, 2024 I193491
J2408464Certificate of AnalysisAug 01, 2024 I193491
D2418382Certificate of AnalysisMar 29, 2024 I193491
D2418395Certificate of AnalysisMar 29, 2024 I193491
D2418397Certificate of AnalysisMar 29, 2024 I193491
D2418438Certificate of AnalysisMar 29, 2024 I193491
D2418439Certificate of AnalysisMar 29, 2024 I193491
K2302455Certificate of AnalysisOct 25, 2023 I193491
K2302461Certificate of AnalysisOct 25, 2023 I193491
K2302462Certificate of AnalysisOct 25, 2023 I193491
G1929133Certificate of AnalysisMay 06, 2023 I193491
J22111147Certificate of AnalysisJun 29, 2022 I193491
J22111197Certificate of AnalysisJun 29, 2022 I193491
J2317035Certificate of AnalysisJun 29, 2022 I193491
F2218041Certificate of AnalysisNov 05, 2021 I193491
F2218042Certificate of AnalysisNov 05, 2021 I193491

Show more⌵

Safety and Hazards(GHS)

Pictogram(s) GHS08,   GHS07
Signal Warning
Hazard Statements

H315:Causes skin irritation

H319:Causes serious eye irritation

H335:May cause respiratory irritation

H373:Causes damage to organs through prolonged or repeated exposure

H361:Suspected of damaging fertility or the unborn child

Precautionary Statements

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352:IF ON SKIN: wash with plenty of water.

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P260:Do not breathe dust/fume/gas/mist/vapors/spray.

P271:Use only outdoors or in a well-ventilated area.

P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P403+P233:Store in a well-ventilated place. Keep container tightly closed.

P362+P364:Take off contaminated clothing and wash it before reuse.

P203:Obtain, read and follow all safety instructions before use.

P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.

P318:if exposed or concerned, get medical advice.

P337+P317:If eye irritation persists: Get medical help.

P332+P317:If skin irritation occurs: Get medical help.

P319:Get medical help if you feel unwell.

Related Documents

Reviews

Customer Reviews

References

1. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B.  (1999)  Identification of a nuclear receptor for bile acids..  Science,  284  (5418): (1362-5).  [PMID:10334992] [10.1021/op500134e]
2. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ.  (2001)  Nuclear receptors and lipid physiology: opening the X-files..  Science,  294  (5548): (1866-70).  [PMID:11729302] [10.1021/op500134e]
3. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM.  (2002)  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity..  J Med Chem,  45  (17): (3569-72).  [PMID:12166927] [10.1021/op500134e]
4. Gai Z et al..  (2017)  Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage..  Sci Rep,  (9815).  [PMID:28852062]

Solution Calculators